Carlos Andrés Gallardo

Dr. Carlos Andrés Gallardo

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
CGCarlos Andrés Gallardo
Carlos Andrés Gallardo
YCY. Cho
Y. Cho
JCJ. Cortés-Rios
J. Cortés-Rios
DVD. Vasquez
D. Vasquez
CPC.D. Pessoa-Mahana
C.D. Pessoa-Mahana
MFMario Faundez
Mario Faundez

1 July 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JRJulio Rodríguez-Lavado
Julio Rodríguez-Lavado
CGCarlos Andrés Gallardo
Carlos Andrés Gallardo
MMMichael Mallea
Michael Mallea
VBVictor Bustos
Victor Bustos
RORodrigo Osorio
Rodrigo Osorio
HPHernán Pessoa-Mahana
Hernán Pessoa-Mahana

3 April 2018 in Archiv der Pharmazie
Verified
Journal Article
Closed access
PDF file
CMClaudio Méndez-Rojas
Claudio Méndez-Rojas
GQGabriel Quiroz
Gabriel Quiroz
MFMario Faundez
Mario Faundez
CGCarlos Andrés Gallardo
Carlos Andrés Gallardo
CPCarlos David Pessoa-Mahana
Carlos David Pessoa-Mahana
HPHernán Pessoa-Mahana
Hernán Pessoa-Mahana

Verified
Journal Article
Open access
PDF file
MFManuel Faundez-Parraguez
Manuel Faundez-Parraguez
CACarlos Alarcón-Miranda
Carlos Alarcón-Miranda
YCYoung hwa Cho
Young hwa Cho
HPHernán Pessoa-Mahana
Hernán Pessoa-Mahana
CGCarlos Andrés Gallardo
Carlos Andrés Gallardo
CPCarlos David Pessoa-Mahana
Carlos David Pessoa-Mahana
The activation of the human cannabinoid receptor type II (CB2R) is known to mediate analgesic and anti-inflammatory processes without the central adverse effects related to cannabinoid receptor type I (CB1R). In this work we describe the synthesis and evaluation of a novel series of N-aryl-2-pyridone-3-carboxamide derivatives tested as human cannabinoid receptor type II (CB2R) agonists. Different cycloalkanes linked to the N-aryl pyridone by an amide group displayed CB2R agonist activity as determined by intracellular [cAMP] levels. The most promising compound 8d exhibited a non-toxic profile and similar potency (EC50 = 112 nM) to endogenous agonists Anandamide (AEA) and 2-Arachidonoylglycerol (2-AG) providing new information for the development of small molecules activating CB2R. Molecular docking studies showed a binding pose consistent with two structurally different agonists WIN-55212-2 and AM12033 and suggested structural requirements on the pyridone substituents that can satisfy the orthosteric pocket and induce an agonist response. Our results provide additional evidence to support the 2-pyridone ring as a suitable scaffold for the design of CB2R agonists and represent a starting point for further optimization and development of novel compounds for the treatment of pain and inflammation.

1 September 2017 in Journal of Herbal Medicine
Verified
Journal Article
Closed access
MLM.E. Letelier
M.E. Letelier
FHF. Hidalgo-Castro
F. Hidalgo-Castro
MLM. López-Valladares
M. López-Valladares
NIN. Ibacache
N. Ibacache
CPC. Pérez
C. Pérez
EOE. Ossandón
E. Ossandón

Verified
Journal Article
Open access
PDF file
YCYoung hwa Cho
Young hwa Cho
HCHery Chung
Hery Chung
JRJavier Romero-Parra
Javier Romero-Parra
PKPoulami Kumar
Poulami Kumar
MAMarco Allarà
Marco Allarà
CPCarlos David Pessoa-Mahana
Carlos David Pessoa-Mahana
The endocannabinoid system (ECS) constitutes a broad-spectrum modulator of homeostasis in mammals, providing therapeutic opportunities for several pathologies. Its two main receptors, cannabinoid type 1 (CB1) and type 2 (CB2) receptors, mediate anti-inflammatory responses; however, their differing patterns of expression make the development of CB2-selective ligands therapeutically more attractive. The benzo[d]imidazole ring is considered to be a privileged scaffold in drug discovery and has demonstrated its versatility in the development of molecules with varied pharmacologic properties. On the other hand, the main psychoactive component of Cannabis sativa, delta-9-tetrahydrocannabinol (THC), can be structurally described as an aliphatic terpenoid motif fused to an aromatic polyphenolic (resorcinol) structure. Inspired by the structure of this phytocannabinoid, we combined different natural product motifs with a benzo[d]imidazole scaffold to obtain a new library of compounds targeting the CB2 receptor. Here, we synthesized 26 new compounds, out of which 15 presented CB2 binding and 3 showed potent agonist activity. SAR analysis indicated that the presence of bulky aliphatic or aromatic natural product motifs at position 2 of the benzo[d]imidazoles ring linked by an electronegative atom is essential for receptor recognition, while substituents with moderate bulkiness at position 1 of the heterocyclic core also participate in receptor recognition. Compounds 5, 6, and 16 were further characterized through in vitro cAMP functional assay, showing potent EC50 values between 20 and 3 nM, and compound 6 presented a significant difference between the EC50 of pharmacologic activity (3.36 nM) and IC50 of toxicity (30–38 µM).